Age Related Macular Degeneration Therapeutics
1. Izervay patent expiration
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947544 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US7803931 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US7538211 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2025
(1 year, 7 days ago) | |
| US9617546 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2027
(11 months from now) | |
| US7579456 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Feb, 2027
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11491176 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
| US11273171 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
| US8236773 | ASTELLAS | Aptamer therapeutics useful in the treatment of complement-related disorders |
Nov, 2026
(8 months from now) | |
| US12016875 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(8 years from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Dosage: SOLUTION
More Information on Dosage
IZERVAY family patents
2. Macugen patent expiration
Treatment: Treatment of vegf mediated ocular disease.
MACUGEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051698 | BAUSCH | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
May, 2015
(10 years ago) | |
| US6113906 | BAUSCH | Water-soluble non-antigenic polymer linkable to biologically active material |
Oct, 2013
(12 years ago) | |
| US5919455 | BAUSCH | Non-antigenic branched polymer conjugates |
Oct, 2013
(12 years ago) | |
| US6011020 | BAUSCH | Nucleic acid ligand complexes |
Jan, 2017
(9 years ago) | |
| US5932462 | BAUSCH | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
Aug, 2016
(9 years ago) | |
Drugs and Companies using PEGAPTANIB SODIUM ingredient
Market Authorisation Date: 17 December, 2004
Dosage: INJECTABLE
More Information on Dosage
MACUGEN family patents
3. Visudyne patent
expiration
Treatment: Use of the drug product in photodynamic therapeutic protocols for the treatment of age-related macular degeneration and related conditions involving unwanted neovasculature in the eye
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5756541 | BAUSCH | Vision through photodynamic therapy of the eye |
Mar, 2016
(9 years ago) | |
| US5770619 | BAUSCH | Method of activating photosensitive agents |
Jan, 2015
(11 years ago) | |
| US5798349 | BAUSCH | Use of green porphyrins to treat neovasculature in the eye |
Aug, 2015
(10 years ago) | |
| US5707608 | BAUSCH | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
Aug, 2015
(10 years ago) | |
Drugs and Companies using VERTEPORFIN ingredient
Market Authorisation Date: 12 April, 2000
Dosage: INJECTABLE
More Information on Dosage
VISUDYNE family patents